Jefferies upgraded Taysha Gene Therapies (TSHA) to Buy from Hold with a price target of $8, up from $2, as the analyst assumed coverage of the stock. Taysha has two catalysts in 2024 with TSHA-102 in Rett Syndrome, notes the analyst, who estimates that Taysha has about a $2.2B peak revenue opportunity in Rett Syndrome. The firm views the setup as attractive, given Taysha’s approach, unmet need, and there being only one clinical-stage gene therapy competitor, namely Neurogene’s (NGNE) NGNE-401.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- TSHA Upcoming Earnings Report: What to Expect?
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies announces RMAT designation granted to TSHA-102 by FDA
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler